The MAPK pathway is upregulated in 66% of melanomas, and many harbor mutated BRAF with the activating BRAF V600E mutation; thus, targeting the RAS/RAF/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathway may be effective in melanoma. This evidence concerns the gene MAP2K7 and melanoma.